Nature Search

SARS-CoV-2-specific cellular and humoral immunity after bivalent BA.4/5 COVID-19-vaccination in previously infected and non-infected individuals

Prior infection or exposure to SARS-CoV-2 may influence immunogenicity and effectiveness of subsequent vaccination to new strains of virus. Here the authors show that immunogenicity of a BA.4/5 mRNA vaccine differed in recipients depending on whether they had been exposed to or infected with an earlier strain of virus.

Rebecca Urschel
Saskia Bronder
Martina Sester
ResearchOpen Access09 Apr 2024
Nature Communications

Volume: 15, P: 1-12
Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens

Multiple formulations and technologies for vaccinating against SARS-CoV-2 exist but how the use of these in homologous or heterologous format impacts immunogenicity is far from clear. Here the authors compare a range of heterologous and homologous SARS-CoV-2 vaccination strategies and assess the induced humoral and cellular immune response.

Verena Klemis
Tina Schmidt
Martina Sester
ResearchOpen Access11 Aug 2022
Nature Communications

Volume: 13, P: 1-11
Reply to: Apolipoprotein C3 induces inflammasome activation only in its delipidated form

Stephen Zewinger
Jochen Reiser
Thimoteus Speer
Research13 Feb 2023
Nature Immunology

Volume: 24, P: 412-413
Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings

The risk of developing active tuberculosis (TB) in individuals with latent TB infection is highly variable within and among different risk groups. A personalized risk predictor was developed to better target preventative treatment to individuals at greatest risk, supporting evidence-based clinical decision-making for latent TB.

Rishi K. Gupta
Claire J. Calderwood
Ibrahim Abubakar
Research19 Oct 2020
Nature Medicine

Volume: 26, P: 1941-1949
Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination

In healthy adults, booster vaccination with an mRNA vaccine, irrespective of the vaccine used for the first dose, was well tolerated and elicited higher levels of spike-specific antibodies and spike-specific T cells than booster vaccination with ChAdOx1 nCov-19.

Tina Schmidt
Verena Klemis
Martina Sester
ResearchOpen Access26 Jul 2021
Nature Medicine

Volume: 27, P: 1530-1535
Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation

Overabundance of apolipoprotein C3 (ApoC3) is associated with atherosclerosis. Speer and colleagues demonstrate that ApoC3 activates the NLRP3 inflammasome via a non-canonical pathway contributing to inflammation and development of atherosclerosis.

Stephen Zewinger
Jochen Reiser
Thimoteus Speer
Research09 Dec 2019
Nature Immunology

Volume: 21, P: 30-41
Potent induction of humoral and cellular immunity after bivalent BA.4/5 mRNA vaccination in dialysis patients

Saskia Bronder
Janine Mihm
Martina Sester
ResearchOpen Access07 Feb 2024
npj Vaccines

Volume: 9, P: 1-12
Time-resolved RNA signatures of CD4+ T cells in Parkinson’s disease

Caroline Diener
Martin Hart
Eckart Meese
ResearchOpen Access21 Jan 2023
Cell Death Discovery

Volume: 9, P: 1-12
miR-34a: a new player in the regulation of T cell function by modulation of NF-κB signaling

Martin Hart
Barbara Walch-Rückheim
Eckart Meese
ResearchOpen Access18 Jan 2019
Cell Death & Disease

Volume: 10, P: 1-14

Search

Filter By:

Search

Quick links